HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Synthelabo SA

Latest From Synthelabo SA

Deals Of The Week: New Remedies Sought From Nature And Old Technologies

Sanofi links with researchers at Germany’s Fraunhofer Gesellschaft in the search for new antibiotics while a European joint venture called Hit Discovery Constance GmbH is set up to conduct high-throughput screening for biotech and academic partners. Also, Moderna Therapeutics bags another major partner, GSK exits its DMD deal with Prosensa, and more.

BioPharmaceutical Europe

Creating Glaxo Wellcome

Glaxo took over Wellcome to boost profits at risk from the Zantac patent expiration. But its R&D managers used the tumult and pain caused by the deal to revitalize an organization which had grown complacent and was ill-equipped to exploit the new technologies which were industrializing drug discovery. Productivity is way up--with no increase in budget. But has Glaxo Wellcome really accomplished its mission or is a continuing series of cost-squeezing mergers still inevitable?

BioPharmaceutical Strategy

The Rich Get Richer

Cash is king and the more you've got, the more investors are willing to give. At least that's the message in medical devices. Start-Up examined recent private offerings of public medical device companies to see if there was a relationship between the cash a company had and the valuation new private investors were willing to afford the company.

Medical Device Business Strategies

The Glaxo/SmithKline Debacle: Unanswered Questions

The proposed merger of SmithKline Beecham and Glaxo Wellcome PLC sent waves of anxiety when it was announced--and relief when it was canceled. The deal ran aground because of disagreements over who would run the company. But the larger questions it raised--about the need for greater critical mass in R&D and the likelihood of future mergers--won't go away so easily.

BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • France
  • Parent & Subsidiaries
  • Synthelabo SA
  • Senior Management
  • Christian Mulliez, VP & CFO
    Herve Guerin, Pres.
    Marc Guyader, VP, Bus. Dev., U.S., Japan
    Regis Dufor, EVP
  • Contact Info
  • Synthelabo SA
    Phone: (33) 14537555
    \B.P. 72-22, Avenue Galilee
    Le Plessis-Robinson, 92352